Biopharmaceutical

New pharmaceutical rules aim to expand medicine access, strengthen supply security, and reshape incentives for EU innovation.

CMS finalized a mandatory Medicare Part B payment model using pricing benchmarks to test lower drug costs while maintaining care quality.

FDA commissioner nominee Heidi Overton defended vaccine safety while declining to take firm positions on mifepristone reviews.

Trump administration drug pricing agreements could lower some costs but may sharply reduce projected Medicare savings.

Anthropic launches a biology lab to support AI-driven life sciences research, advancing disease-focused ambitions amid growing safety concerns.

FDA issues a request for information to gather feedback on challenges, scientific needs, and regulatory approaches for advancing botanical drug products.

Health Canada seeks public input on a proposed review queue pilot designed to strengthen supply security and reduce drug shortage risks.

Health Canada introduces a reliance framework to accelerate access to treatments, beginning with pediatric and veterinary drugs.